SCOUT Shows Challenges Of Cardiovascular Outcomes Trials In Obesity
Executive Summary
Abbott’s SCOUT study of Meridia’s cardiovascular safety shows the design, enrollment and interpretation challenges facing obesity drug developers if FDA were to require CV outcomes studies either pre- or post-approval.
You may also be interested in...
Obesity Drug Developers Aim To Navigate Regulatory Backroads
The major lesson of FDA’s serial rejection of three obesity drugs in a six-month span is that safety is paramount in the weight loss space. That’s agreed. But beyond that, it’s tough to know what to expect, and obesity drug developers face an uncertain regulatory path going forward.
Clinical Trial Diversity Requires Sponsors Work With An Assortment Of Patient Advocates, Community Organizations
US FDA oncology officials are concerned that the entities sponsors are consulting in developing and implementing clinical trial diversity plans are not sufficiently diverse themselves and do not represent patients in underserved communities.